StrainprintTM Technologies Ltd. (“StrainprintTM“) — a leader in cannabis patient data collection — is proud to announce the launch of a revolutionary Cannabis Tracking APP & platform. The mobile APP has been created by patients for patients and is now available for both Apple iOS & Android.
StrainprintTM enables cannabis patients to track and understand the efficacy of their cannabis use by strain, quantity, method of ingestion and dose. Using standardized pain scales, this much-needed data will help patients use cannabis more effectively and help clinicians to better tailor therapeutic regimens. Strainprint’s database contains all strains and products available under the Access to Cannabis for Medical Purposes Regulations program (ACMPR). Patients can also add their own unique/personal strains.
The HIPAA and PIPEDA compliant solution is identifying valuable and fascinating efficacy trends across a variety of medical conditions. This information will enable patients, producers, clinicians and other supply chain partners to better understand the needs of patients and how specific cannabinoids affect a multitude of conditions.
“StrainprintTM helps patients and medical practitioners to better understand how specific cannabis genetics and ingestion methods provide the best therapy for over 170 applicable medical conditions,” said Alexander Repetski, Chief Communications Officer. “By using this data to fine-tune their treatment, StrainprintTM will assist in improving the quality of life for those using cannabis. The academic community will also benefit greatly fron this tool, and will assist to accelerate research efforts and further enhance the understanding of cannabis,” he added.
“The importance of this real-time crowd-sourced data is integral to both governmental bodies and the academic community to accelerate research efforts and further enhance the understanding of cannabis,” said StrainprintTM President, David Berg. “With the pending legalization of recreational cannabis in Canada, the data acquired by Strainprint also holds significance in determining many facets of regulations concerning public health and safety,” he added.
“StrainprintTM was created out of necessity. As a patient who had limited knowledge about cannabis, the need for a tool to help guide and enhance treatment seemed almost essential. It didn’t exist, and that’s why we spent several years developing it. We’re continually improving the software to ensure a simple and rewarding experience,” said Stephanie Karasick, Founder & Chief Strategy Officer.
About StrainprintTM:
Founded in 2016, StrainprintTM Technologies Ltd. is a Toronto-based company providing enterprise grade analytics and consumer solutions for the medical cannabis industry. StrainprintTMmanages the gathering and analysis of real-time cannabis consumption data and ranks specific strain efficacy against conditions and related symptoms. Analyzing anonymous patient treatment data and efficacy measures will help to identify new treatment protocols for the medical community and patients. StrainprintTM also works with commercial producers and clinics to provide advanced intelligence to optimize grow operations and treatment methods. For more information visit www.strainprint.ca. facebook, twitter, linkedin.
credit:420intel.com